• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Immunovant Inc.

    4/30/25 4:06:19 PM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMVT alert in real time by email
    S-8 1 imvt-20250430xsx8.htm S-8 Document



    As filed with the U.S. Securities and Exchange Commission on April 30, 2025
    Registration No. 333-                

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ______________
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
    ___________________
    IMMUNOVANT, INC.
    (Exact name of registrant as specified in its charter)
    ___________________
    Delaware
     (State of incorporation or organization)
    83-2771572
     (I.R.S. Employer Identification No.)
    320 West 37th Street
    New York, NY
     (Address of principal executive office)
     
    10018
    (Zip Code)

    Immunovant, Inc. 2019 Equity Incentive Plan
    (Full title of the plan)
    Tiago Girao
    Chief Financial Officer
    Immunovant, Inc.
    320 West 37th Street
    New York, NY 10018
    (917) 580-3099
    (Name, address and telephone number, including area code, of agent for service)
    Copies to:
    Marc Recht
    Brandon Fenn
    Cooley LLP
    500 Boylston Street, 14th Floor
    Boston, MA 02116
    (617) 937-2300
    __________________
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large Accelerated filer    ☒
    Accelerated filer    ☐
    Non-accelerated filer    ☐
    Smaller reporting company    ☐

    Emerging growth company    ☐





    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐







    EXPLANATORY NOTE
    We are filing this Registration Statement on Form S-8 with the Securities and Exchange Commission (the “SEC”) for the purpose of registering an additional 6,804,463 shares of our common stock (“Common Stock”) under the 2019 Equity Incentive Plan, which shares of Common Stock are in addition to the shares of Common Stock registered on our Registration Statements on Form S-8 (File Nos. 333-236665, 333-239537, 333-262087, 333-265477, 333-271138 and 333-278686), filed with the SEC on February 26, 2020, June 29, 2020, January 10, 2022, June 8, 2022, April 5, 2023 and April 15, 2024 respectively (the “Prior Forms S-8”). In accordance with the instructional note to Part I of Form S-8 as promulgated by the SEC, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.
    PART II
     
    ITEM 3.
    INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE.
    Pursuant to General Instruction E to Form S-8, the contents of the Prior Forms S-8 are incorporated by reference herein. In addition, the following documents we filed with the SEC are incorporated by reference into this Registration Statement:
    (a) Our Annual Report on Form 10-K for the fiscal year ended March 31, 2024 (the “Annual Report”), filed with the Commission on May 29, 2024;
    (b) Our Quarterly Reports on Form 10-Q for the quarterly period ended June 30, 2024, filed with the SEC on August 6, 2024, for the quarterly period ended September 30, 2024, filed with the SEC on November 7, 2024 and for the quarterly period ended December 31, 2024, filed with the SEC on February 6, 2025;
    (c) the information specifically incorporated by reference in our Annual Report on Form 10-K for the year ended March 31, 2024 from our definitive proxy statement relating to our 2024 annual meeting of stockholders, filed with the SEC on June 26, 2024;
    (d) Our Current Reports on Form 8-K filed with the SEC on August 13, 2024, September 9, 2024 (only with respect to information filed under item 8.01), November 7, 2024 (only with respect to information filed under item 8.01), January 13, 2025 (only with respect to information filed under items 1.01 and 3.02), January 24, 2025 (only with respect to information filed under item 8.01), March 19, 2025 (only with respect to information filed under item 8.01) and April 21, 2025 (only with respect to information filed under items 5.02 and 8.01);
    (e) The description of the Common Stock, which is contained in our Registration Statement on Form 8-A, filed with the SEC on May 9, 2019 (File No. 001-38906) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description; and

    All documents, reports and definitive proxy or information statements filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.





    ITEM 8.    EXHIBITS.
    Incorporated by Reference
    Exhibit
    Number
    DescriptionSchedule
    Form
    File NumberExhibitFiling Date
    4.1
    Amended and Restated Certificate of Incorporation of Immunovant, Inc.
    8-K001-389063.1December 20, 2019
    4.2
    Amended and Restated Bylaws of Immunovant, Inc.
    8-K001-389063.2December 20, 2019
    5.1*
    Opinion of Cooley LLP.
    23.1*
    Consent of Ernst & Young LLP, independent registered public accounting firm.
    23.3*
    Consent of Cooley LLP (included in Exhibit 5.1).
    24.1*
    Power of Attorney (included on the signature page of this Form S-8).
    99.1
    2019 Equity Incentive Plan.
    10-K001-3890610.3
    June 29, 2020
    99.2
    Forms of Option Grant Notices and Option Agreements under 2019 Equity Incentive Plan.
    10-K001-3890610.3.1
    June 29, 2020
    99.3
    Forms of Restricted Stock Unit Grant Notices and Award Agreements under 2019 Equity Incentive Plan.
    10-K001-3890610.3.2
    June 29, 2020
    99.4
    UK Sub-Plan to the Immunovant, Inc. 2019 Equity Incentive Plan
    10-Q001-3890610.1February 3, 2023
    99.5
    Form of Stock Option Grant Notice and Agreement for the UK Sub-Plan
    10-Q001-3890610.2February 3, 2023
    99.6
    Form of Restricted Stock Unit Grant Notice and Agreement for the UK Sub-Plan
    10-Q001-3890610.3February 3, 2023
    107*
    Filing Fee Table
    *Filed herewith.







    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in New York, New York on this 30th day of April, 2025.
    Immunovant, Inc.
    By:     /s/ Eric Venker    
    Eric Venker, M.D., Pharm.D.
    Chief Executive Officer
    POWER OF ATTORNEY
    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Eric Venker, M.D., Pharm.D. and Tiago Girao, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
    SignatureTitle
    Date
               /s/ Eric Venker     
     Eric Venker, M.D., Pharm.D.
    Chief Executive Officer and Director
    (
    Principal Executive Officer)
    April 30, 2025
              /s/ Tiago Girao     
    Tiago Girao
    Chief Financial Officer
    (
    Principal Financial and Accounting Officer)
    April 30, 2025
               /s/ Frank M. Torti    
    Frank M. Torti, M.D.
    Executive Chairperson of the Board of Directors
    April 30, 2025
                /s/ Jacob Bauer    
      Jacob Bauer
    Director
    April 30, 2025
                /s/ Andrew Fromkin    
      Andrew Fromkin
    Director
    April 30, 2025
               /s/ Douglas Hughes     
      Douglas Hughes
    Director
    April 30, 2025
                    /s/ Atul Pande    
      Atul Pande, M.D.
    Director
    April 30, 2025
                    /s/ Robert Susman     
     Robert Susman
    Director
    April 30, 2025



    Get the next $IMVT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMVT

    DatePrice TargetRatingAnalyst
    3/3/2025$20.00Hold
    Jefferies
    1/3/2025Outperform → Peer Perform
    Wolfe Research
    10/10/2024$36.00Outperform
    Raymond James
    10/9/2024$47.00 → $53.00Outperform
    Oppenheimer
    3/28/2024$50.00Outperform
    Oppenheimer
    3/13/2024$50.00Buy
    Goldman
    2/20/2024$51.00Overweight
    JP Morgan
    2/15/2024$55.00Outperform
    Wolfe Research
    More analyst ratings

    $IMVT
    Leadership Updates

    Live Leadership Updates

    See more
    • Ankyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of Directors

      Ankyra is pleased to announce the appointment of Dr. Julia G. Butchko and Ms. Tara Withington to the Board of Directors effective September 25, 2024. They will both serve as independent board members and their appointment brings the total board composition to seven directors. "We are delighted to welcome Dr. Butchko and Ms. Withington to the Board", stated Tillman Gerngross, PhD, Chairman of the Ankyra Board of Directors. "These accomplished individuals bring a fresh perspective to Ankyra at a critical time in the company's growth." Howard L. Kaufman, MD, President and Chief Executive Officer at Ankyra added "I am especially enthusiastic about working with Dr. Butchko and Ms. Withington sin

      9/23/24 8:00:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Appoints Mark Levine as Chief Legal Officer

      Mr. Levine adds valuable experience to the leadership team as Immunovant accelerates the development of batoclimab with the expected initiation of three pivotal trials in 2022 NEW YORK, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, announced the appointment of Mark Levine as Chief Legal Officer. "We are extremely pleased to welcome Mark Levine as Immunovant's Chief Legal Officer," said Pete Salzmann, M.D., Chief Executive Officer. "Mark's broad legal experience at biopharmaceutical companies ranging from early-stage development through commercialization wil

      1/25/22 8:30:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Appoints Renee Barnett as Chief Financial Officer

      Ms. Barnett brings a wealth of financial experience to ImmunovantExpands executive leadership team as Immunovant plans to return to the clinic across multiple indications NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced the appointment of Renee Barnett, as Chief Financial Officer, effective October 4, 2021. "We are incredibly excited to have Renee Barnett join the Immunovant management team at this important time for our company," said Pete Salzmann, M.D., Chief Executive Officer. "Renee brings a deep understanding of drug developmen

      9/15/21 7:00:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Immunovant Inc.

      SC 13G/A - Immunovant, Inc. (0001764013) (Subject)

      11/12/24 10:32:13 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Immunovant Inc. (Amendment)

      SC 13G/A - Immunovant, Inc. (0001764013) (Subject)

      2/14/24 8:47:41 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Immunovant Inc.

      SC 13G - Immunovant, Inc. (0001764013) (Subject)

      2/9/24 9:16:06 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMVT
    SEC Filings

    See more

    $IMVT
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $IMVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $IMVT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $IMVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 144 filed by Immunovant Inc.

      144 - Immunovant, Inc. (0001764013) (Subject)

      5/21/25 4:24:45 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Immunovant Inc.

      144 - Immunovant, Inc. (0001764013) (Subject)

      5/19/25 4:40:29 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Immunovant Inc.

      S-8 - Immunovant, Inc. (0001764013) (Filer)

      4/30/25 4:06:19 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

      Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (with 64% mean IgG reduction)Initial CIDP results from Period 1, following standard of care washout, demonstrate a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in those patients who achieved an IgG lowering greater than 70%In both batoclimab studies, deeper IgG reductions correlated with better clinical outcomes across a range of assessments and timepointsINDs active for both MG and CIDP wi

      3/19/25 7:45:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

      NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call. Webcast DetailsThe company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The live webcast

      3/18/25 4:32:00 PM ET
      $IMVT
      $ROIV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

      NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call. Webcast Details The company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The l

      3/18/25 4:32:00 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies initiated coverage on Immunovant Sciences with a new price target

      Jefferies initiated coverage of Immunovant Sciences with a rating of Hold and set a new price target of $20.00

      3/3/25 7:24:04 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Sciences downgraded by Wolfe Research

      Wolfe Research downgraded Immunovant Sciences from Outperform to Peer Perform

      1/3/25 7:34:55 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James resumed coverage on Immunovant Sciences with a new price target

      Raymond James resumed coverage of Immunovant Sciences with a rating of Outperform and set a new price target of $36.00

      10/10/24 8:38:30 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Roivant Sciences Ltd. bought $336,900,200 worth of shares (16,845,010 units at $20.00), increasing direct ownership by 21% to 96,650,341 units (SEC Form 4)

      4 - Immunovant, Inc. (0001764013) (Issuer)

      1/15/25 4:36:38 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Roivant Sciences Ltd. was granted 4,473,684 shares and bought $58,000,008 worth of shares (1,526,316 units at $38.00), increasing direct ownership by 8% to 79,805,331 units (SEC Form 4)

      4 - Immunovant, Inc. (0001764013) (Issuer)

      10/4/23 5:15:20 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Girao Tiago was granted 208,388 shares (SEC Form 4)

      4 - Immunovant, Inc. (0001764013) (Issuer)

      5/5/25 7:30:09 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Susman Robert Graham was granted 25,016 shares (SEC Form 4)

      4 - Immunovant, Inc. (0001764013) (Issuer)

      5/5/25 7:30:05 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Bauer Jake was granted 25,016 shares (SEC Form 4)

      4 - Immunovant, Inc. (0001764013) (Issuer)

      5/5/25 7:30:07 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMVT
    Financials

    Live finance-specific insights

    See more
    • Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

      NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call. Webcast DetailsThe company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The live webcast

      3/18/25 4:32:00 PM ET
      $IMVT
      $ROIV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Immunovant Reports Financial Results for the Quarter Ended December 31, 2024

      Lead asset IMVT-1402 rapidly progressing with now six Investigational New Drug (IND) applications cleared and pivotal studies in Graves' disease (GD) and difficult-to-treat rheumatoid arthritis (D2T RA) now enrolling with 2.25ml autoinjector Additional results from batoclimab proof-of-concept study in GD, including 6-month treatment free remission data expected in summer 2025 Top line results of the batoclimab trial in myasthenia gravis (MG) and initial results from period 1 of batoclimab trial in chronic inflammatory demyelinating polyneuropathy (CIDP) expected by March 31, 2025 Pro forma cash balance of approximately $825 million as of December 31, 2024, including approximately $450 mil

      2/6/25 6:30:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

      Five Investigational New Drug (IND) applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402Proof of concept data from batoclimab trial in Graves' disease (GD) demonstrate potential of deeper IgG reduction with potent FcRn inhibition to transform treatment for GD patients who are not well controlled on antithyroid drugs (ATDs); initiation of potentially registrational trial to evaluate IMVT-1402 in GD expected by year endIND cleared for IMVT-1402 in rheumatoid arthritis (RA), with potential best-in-class profile in difficult-to-treat (D2T) RA; initiation of potentially registrational trial to evaluate IMVT-1402 in D2T RA expected by March 31, 2025O

      11/7/24 6:30:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care